Clinical trial
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in…
NCT00037609 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00037609 |
|---|---|
| Title | Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients |
| Official title | Phase I-II Study to Evaluate Safety, Efficacy and Pharmacokinetic Interactions Between Capecitabine (XELODA) and Exisulind (APTOSYN) in Patients With Metastatic Breast Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Cell Pathways Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | Capecitabine, Exisulind |
| Enrollment | 35 |
| Start date | Jan 1, 2001 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | May 20, 2002 |
| Last update posted | Oct 24, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: